Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several mechanistic and boxed-warning-related safety claims align with the provided label text, but many key efficacy/indication, boxed warning items, adverse reaction details, and manufacturing/biosimilar/cost/competition claims are unsupported or not present in the supplied label excerpts.
Category Scores
Accurate Statements
Tofacitinib is an active pharmaceutical ingredient (API) used in medications like Xeljanz and Xeljanz-XR.
Not directly supported in the provided label excerpt (no explicit mention of API or Xeljanz/Xeljanz-XR brand usage in the supplied text).
Tofacitinib is a Janus kinase (JAK) inhibitor.
12.1 Mechanism of Action: 'Tofacitinib is a Janus kinase (JAK) inhibitor.'
JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function.
12.1 Mechanism of Action: 'JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function.'
Within the signaling pathway, JAKs phosphorylate and activate STATs which modulate intracellular activity including gene expression.
12.1 Mechanism of Action: 'JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression.'
Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.
12.1 Mechanism of Action: 'Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.'
The label describes that JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2).
12.1 Mechanism of Action: 'JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2).'
Tofacitinib inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 values (label provides IC50 values for combinations).
12.1 Mechanism of Action: 'Tofacitinib inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 of 406, 56, and 1377 nM, respectively.'
Tofacitinib has a boxed warning regarding serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis (as described in the provided 'WARNING:' section).
5 WARNINGS AND PRECAUTIONS: 'WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS'
The label states that serious infections include tuberculosis and invasive fungal infections.
5 WARNING section under SERIOUS INFECTIONS: 'including tuberculosis (TB)' and 'Invasive fungal infections, including cryptococcosis and pneumocystosis.'
The label states thrombosis (including pulmonary embolism and deep venous thrombosis) has occurred and recommends avoiding in patients at risk and discontinuing and evaluating with symptoms.
5 WARNING section THROMBOSIS: 'Thrombosis, including pulmonary embolism, deep venous thrombosis, and arterial thrombosis have occurred...' and 'Avoid tofacitinib extended-release tablets in patients at risk. Discontinue... and promptly evaluate patients with symptoms of thrombosis.'
The label states malignancies including lymphomas and solid tumors have occurred; higher rates of malignancies and lymphomas/lung cancers were observed compared to TNF blockers in RA patients.
5 WARNING section MALIGNANCIES: 'Malignancies, including lymphomas and solid tumors, have occurred...' and 'Lymphomas and lung cancers were observed at a higher rate...'
The label states that RA patients 50 years and older with cardiovascular risk factors had a higher rate of major adverse cardiovascular events including stroke, and discontinuation is recommended after myocardial infarction or stroke.
5 WARNING section MAJOR ADVERSE CARDIOVASCULAR EVENTS: 'higher rate of major adverse cardiovascular events (MACE) ... defined as ... stroke' and 'Discontinue...' after MI or stroke.
Unsupported Statements
Tofacitinib is an active pharmaceutical ingredient (API) used in medications like Xeljanz and Xeljanz-XR.
The provided label excerpt does not explicitly state 'API' or mention Xeljanz/Xeljanz-XR usage; it only describes tofacitinib extended-release tablets and includes manufacturing/chemical description.
Tofacitinib specifically targets JAK1 and JAK3 and to a lesser extent JAK2.
The label provides in vitro IC50 values for JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations; it does not state a specific 'targets JAK1 and JAK3 and to a lesser extent JAK2' conclusion in those exact terms.
The enzymes JAK1, JAK3, and JAK2 play a role in signaling pathways of certain cytokines and growth factors involved in inflammation and immune response.
The label excerpt describes cytokine/growth factor-receptor signaling and immune cell function, but does not explicitly tie JAK1/JAK3/JAK2 as a set 'involved in inflammation' in the specific form claimed.
By inhibiting these signaling pathways, tofacitinib can reduce inflammation and modulate the immune system.
The mechanism section describes STAT phosphorylation/activation prevention, but the provided excerpt does not explicitly say 'reduce inflammation' or 'modulate the immune system.'
Tofacitinib works by blocking the action of Janus kinases (JAKs).
The label states tofacitinib prevents STAT phosphorylation/activation at the point of JAKs, but does not use the exact wording 'blocking the action of JAKs.'
JAKs are activated when cytokines bind to receptors on the cell surface.
The label describes transmission arising from cytokine or growth factor-receptor interactions on the cellular membrane, but does not explicitly state 'JAKs are activated when cytokines bind to receptors on the cell surface.'
Once activated, JAKs help transmit signals from the cell surface into the cell's nucleus, influencing gene expression related to inflammation and immunity.
The label excerpt states JAKs phosphorylate/activate STATs which modulate gene expression, but does not explicitly describe 'cell surface into the cell's nucleus' or 'inflammation and immunity' in that phrasing.
Tofacitinib's inhibition of JAK1 and JAK3 pathways disrupts signaling cascades, leading to reduction of inflammatory processes associated with certain autoimmune diseases.
The label excerpt does not explicitly state 'reduction of inflammatory processes' or 'certain autoimmune diseases' in mechanism form.
Tofacitinib is prescribed for moderate to severe active rheumatoid arthritis.
The provided excerpt does not include '1 INDICATIONS AND USAGE' content; therefore specific indication language is not verifiable from supplied text.
Tofacitinib is prescribed for active psoriatic arthritis.
Indication details are not included in the provided label excerpt.
Tofacitinib is prescribed for ulcerative colitis.
Indication details are not included in the provided label excerpt.
Tofacitinib is indicated for active polyarticular course juvenile idiopathic arthritis in patients three years of age and older.
The provided excerpt includes only a pediatric use limitation ('safety and effectiveness... not established') and does not provide the requested indication language.
Common side effects of tofacitinib may include upper respiratory tract infections.
The provided excerpt lists clinically significant adverse reactions elsewhere but does not provide a list of 'common side effects' or URTI specifically.
Common side effects of tofacitinib may include headache.
The provided excerpt does not include a 'common side effects' list or headache.
Common side effects of tofacitinib may include diarrhea.
The provided excerpt does not include a 'common side effects' list or diarrhea.
Tofacitinib may increase the risk of serious infections, such as tuberculosis.
The boxed warning excerpt does state increased risk of serious infections including TB, but the claim uses 'may increase' phrasing and 'such as' without specifying the label's detailed guidance. While directionally consistent, the label excerpt contains the info; however this item is already captured more precisely in the supported list. Marked unsupported only if treated as generic 'common adverse effect'—but TB is explicitly included. (Note: see category scoring.)
Tofacitinib may increase the risk of serious infections, such as invasive fungal infections.
Invasive fungal infections are explicitly included in the label's serious infection list; this is supported, but the excerpt did not phrase it as a 'may increase risk' sentence. (Note: see category scoring.)
Tofacitinib may increase the risk of certain cancers, particularly lymphoma.
Label supports malignancies and lymphomas, but the provided excerpt does not use the exact 'particularly lymphoma' phrasing as a general risk statement; it describes observed malignancies and higher rates in comparisons.
Tofacitinib may increase the risk of certain cancers, particularly lung cancer.
Label supports higher rates of lung cancers in RA comparison context, but does not state as a general 'lung cancer particularly' risk sentence.
Tofacitinib has a boxed warning regarding increased risk of blood clots.
The label boxed warning excerpt states THROMBOSIS but does not use 'blood clots' terminology. It is conceptually covered by 'thrombosis,' but exact phrasing is not in the provided excerpt.
Tofacitinib has a boxed warning regarding increased risk of stroke.
The label boxed warning excerpt includes MACE defined to include 'stroke' and a higher rate of MACE, but the claim reduces it to 'boxed warning regarding increased risk of stroke' without the label's context of RA population.
Tofacitinib has a boxed warning regarding increased risk of death in certain patient populations.
The label boxed warning excerpt mentions increased all-cause mortality in RA patients 50+ with CV risk factors; the claim is more general 'increased risk of death.'
The development of biosimilars for tofacitinib is contingent on the expiry of relevant patents and regulatory pathways.
No biosimilar/patent content is present in the provided label excerpts.
Once primary patents expire and regulatory agencies establish pathways for biosimilar approval, manufacturers can pursue development and marketing of tofacitinib biosimilars.
No biosimilar/patent or regulatory pathway content is present in provided label excerpts.
The availability of biosimilars typically leads to increased competition and potentially lower drug costs.
No biosimilar economics/cost statements are present in the provided label excerpts.
Tofacitinib is manufactured using complex chemical synthesis processes.
No manufacturing process description (beyond chemical identity and tablet composition) is present in the provided excerpts.
Tofacitinib API production adheres to strict Good Manufacturing Practice (GMP) guidelines to ensure purity, quality, and consistency.
The provided excerpt includes chemistry/tablet composition and manufacturing location, but does not mention GMP or API production adherence.
Clinical trials of tofacitinib have demonstrated its ability to reduce disease activity in rheumatoid arthritis.
No 'clinical studies' efficacy results are included in the provided excerpt.
Clinical trials of tofacitinib have demonstrated its ability to reduce disease activity in psoriatic arthritis.
No clinical studies efficacy results are included in the provided excerpt.
Clinical trials of tofacitinib have demonstrated its ability to reduce disease activity in ulcerative colitis.
No clinical studies efficacy results are included in the provided excerpt.
Clinical trials ... have demonstrated improved patient-reported outcomes in rheumatoid arthritis/psoriatic arthritis/ulcerative colitis.
No such patient-reported outcome details are present in the provided excerpt.
Clinical data for tofacitinib identified specific risks associated with its use.
While risks are described in warnings/precautions, the claim is broad and not tied to the label's provided specific risk-identification process.
Safety warnings and monitoring recommendations for tofacitinib were developed based on identified specific risks.
The label describes warnings and monitoring, but does not state a development rationale.
The cost of tofacitinib can vary depending on dosage, formulation ... country of purchase, and insurance coverage.
No pricing/cost information is present in the provided label excerpt.
Tofacitinib is a prescription medication for chronic conditions.
The provided excerpt does not state chronic condition usage or prescription status.
Tofacitinib is generally considered a high-cost therapy.
No cost-related statements are present in the provided excerpt.
Tofacitinib competes with other JAK inhibitors such as baricitinib / upadacitinib.
No market competition or comparative drug positioning statements are present in the label excerpt.
Tofacitinib competes with biologic therapies such as TNF inhibitors including adalimumab / etanercept.
No market competition statements are present in the label excerpt.
Tofacitinib competes with IL-inhibitors.
No market competition statements are present in the label excerpt.
Contradictions
Important Omissions
Indication-specific, labeled wording for approved uses (e.g., RA/PsA/UC/JIA) and corresponding patient age/population criteria.
Importance:
Moderate
Dosage and administration details (e.g., recommended doses, adjustments, and administration instructions) corresponding to the claims made about indications.
Importance:
Moderate
Specific adverse reactions and their frequency (the label lists clinically significant adverse reactions but the excerpt does not provide 'common side effects' like headache/diarrhea/URTI).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported or unverified claims about indications and 'common side effects' could mislead users; however, the response also includes several label-supported boxed warning elements (serious infections including TB/fungal infections, malignancy/lymphoma and lung cancer in context, MACE including stroke, and thrombosis) and mechanism statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Many claims (approved indications, common side effects, biosimilars/cost/competition, and some warning phrasing) are not supported by the provided label excerpts, and key label sections like Indications and Clinical Studies are not included for verification.
Suggested Improvement
Restrict claims to the supplied label text (e.g., 12.1 mechanism and 5 boxed warnings details) and avoid adding unverified indication wording, 'common side effects' lists, manufacturing/GMP assertions, biosimilar/patent/economic statements, and market competition claims unless supported by the FDA label sections provided.